Anticancer potential of curcumin: preclinical and clinical studies.

By Bharat B. Aggarwal, Anushree Kumar, A. Bharti. Anticancer Research, 2003

2,746 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/4f23c66d321d22946a67d79828a4646a85784846

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. (2009, background): “Preclinical cancer research using curcumin has shown it inhibits carcinogenesis in a number of cancer types, including colorectal, pancreatic, gastric, prostate, hepatic, breast, and oral cancers, and leukemia, and at various stages of carcinogenesis.(6) Antiinflammatory mechanisms implicated in the”
Multiple biological activities of curcumin: a short review. (2006, background): “…basis of anti-carcinogenic and chemopreventive effects of curcumin is attributed to its effect on several targets including transcription factors, growth regulators, adhesion molecules, apoptotic genes, angiogenesis regulators and cellular signaling molecules (reviewed in Aggarwal et al., 2003).”
Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy (2007, background): “Peer reviewed publications numbering in the 100 s have reiterated the potency of curcumin against a plethora of human cancer lines in the laboratory (selected reviews include [1,4-6,40,41]).”
Curcumin: Preventive and Therapeutic Properties in Laboratory Studies and Clinical Trials (2008, unknown): “AD, Alzheimer disease; ADI, acceptable daily intake; Ang, angiopoietin; AOM, azoxymethane; AP-1, activator protein-1; APC, adenomatous polyposis coli; ARE, antioxidant response element; ARNT, aryl hydrocarbon receptor nuclear translocator; ATF3, activating transcription factor 3; BDMC-A, bis-1,7-(2-”
Deubiquitination and Stabilization of PD-L1 by CSN5 (2016, background): “Cancer Cell 30, 925–939, December 12, 2016 937 diseases, including many types of cancer in human clinical trials (Aggarwal et al., 2003).”
Curcumin, a component of golden spice: from bedside to bench and back. (2014, background): “Curcumin inhibits experimental allergic encephalomyelitis by blocking interleukin (IL)-12 signaling in T cells, suggesting that it would be effective in the treatment ofmultiple sclerosis (Aggarwal et al., 2003).”
“Spicing Up” of the Immune System by Curcumin (2007, background): “Apparently, curcumin is a pluripotent pharmacological agent that utilizes multiple molecular pathways to leave its imprint on biological systems (47).”
Curcumin: Biological, Pharmaceutical, Nutraceutical, and Analytical Aspects (2019, background): “Curcumin shows maximum absorption at 430 nm in methanol and 415–420 nm in acetone [5,57].”
Curcumin: An Anti-Inflammatory Molecule from a Curry Spice on the Path to Cancer Treatment (2011, background): “A pleiotropic activity in the cell is provided by ability of curcumin to inhibit multiple levels of the NF-κB, AP-1, and JNK signalling pathways [98-100].”
The Chemistry of Curcumin: From Extraction to Therapeutic Agent (2014, background): “The largest worldwide producer of turmeric is India, where it has been used as a home-remedy for several ailments for ages [1–4].”